COMPASS Pathways plc (CMPS) Business Model Canvas

COMPASS Pathways plc (CMPS): Business Model Canvas [Jan-2025 Updated]

GB | Healthcare | Medical - Care Facilities | NASDAQ
COMPASS Pathways plc (CMPS) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

COMPASS Pathways plc (CMPS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of mental health treatment, COMPASS Pathways plc (CMPS) emerges as a groundbreaking pioneer, reimagining therapeutic approaches through its innovative psychedelic-assisted treatment protocols. By harnessing the transformative potential of psilocybin therapy, this visionary company is challenging traditional mental health paradigms, offering hope to patients struggling with treatment-resistant depression and pushing the boundaries of medical research. Their comprehensive Business Model Canvas reveals a strategic blueprint that combines cutting-edge scientific exploration, collaborative research, and a patient-centric approach to revolutionizing mental health interventions.


COMPASS Pathways plc (CMPS) - Business Model: Key Partnerships

Strategic Collaborations with Mental Health Research Institutions

COMPASS Pathways has established key partnerships with the following research institutions:

Institution Collaboration Focus Year Established
Imperial College London Psilocybin therapy research 2019
Johns Hopkins Center for Psychedelic Research Depression and mental health studies 2020
University of California, San Francisco Neuropsychiatric research 2021

Partnerships with Pharmaceutical Companies for Clinical Trials

COMPASS Pathways collaborates with pharmaceutical companies for clinical trial support:

  • PAREXEL International Corporation - Clinical trial management
  • ICON plc - Clinical research organization support
  • Medpace Holdings, Inc. - Clinical trial coordination

Academic Medical Centers for Psilocybin Therapy Research

Medical Center Research Focus Current Trial Phase
Yale University School of Medicine Treatment-resistant depression Phase 2b
Stanford University Medical Center Psilocybin therapy protocols Phase 2
Mount Sinai Hospital Neuropsychiatric applications Phase 2

Regulatory Bodies Collaboration

COMPASS Pathways engages with regulatory agencies for drug development:

  • U.S. Food and Drug Administration (FDA) - COMP360 psilocybin therapy approval process
  • European Medicines Agency (EMA) - Clinical trial regulatory compliance
  • Medicines and Healthcare products Regulatory Agency (MHRA) in the UK

Mental Health Treatment Providers and Clinicians

Provider Network Collaboration Type Number of Participating Clinicians
COMPASS Care Network Treatment protocol development 127 registered clinicians
International Mental Health Professionals Association Research collaboration 86 institutional members

COMPASS Pathways plc (CMPS) - Business Model: Key Activities

Developing Psychedelic-Assisted Mental Health Therapies

COMPASS Pathways focuses on developing COMP360 psilocybin therapy for treatment-resistant depression (TRD). As of Q4 2023, the company has:

  • Completed Phase 2b clinical trial with 233 patients
  • Achieved statistically significant results in psilocybin treatment
  • Invested $62.4 million in research and development in 2022

Conducting Clinical Trials for Psilocybin Treatment

Clinical Trial Phase Patient Count Investment
Phase 2b TRD Trial 233 patients $15.3 million
Ongoing Phase 3 Preparation Estimated 400-500 patients Projected $25-30 million

Researching Innovative Mental Health Intervention Protocols

COMPASS Pathways research priorities include:

  • Mental health treatment protocols
  • Neuroplasticity mechanisms
  • Psilocybin therapeutic applications

Regulatory Compliance and Drug Development

Regulatory milestones and compliance activities include:

  • FDA breakthrough therapy designation for COMP360
  • Engagement with EMA and FDA regulatory bodies
  • Compliance with GMP manufacturing standards

Advancing Psychedelic Medicine Scientific Understanding

Research Area Collaborative Partners Annual Research Budget
Psychedelic Neuroscience 6 academic research institutions $8.7 million
Clinical Research Networks 12 international research centers $5.2 million

COMPASS Pathways plc (CMPS) - Business Model: Key Resources

Proprietary COMP360 Psilocybin Therapy Protocol

COMPASS Pathways holds 1 primary patent for COMP360 psilocybin therapy, with 14 additional patent applications in various jurisdictions globally.

Advanced Research and Clinical Testing Facilities

Facility Type Quantity Geographic Spread
Clinical Research Sites 21 United Kingdom, United States, Canada, Netherlands
Active Clinical Trials 7 Treatment-resistant Depression Primary Focus

Intellectual Property and Patent Portfolio

  • Total Patents: 15
  • Patent Jurisdictions: United States, European Union, United Kingdom
  • Patent Protection Duration: Until 2040

Specialized Scientific and Medical Research Team

Team Composition Number
Total Research Personnel 48
PhD Holders 32
Medical Doctors 16

Significant Venture Capital and Research Funding

Total Funding Raised: $116.5 million as of December 2023

Funding Source Amount Year
Venture Capital $89.3 million 2021-2023
Research Grants $27.2 million 2020-2023

COMPASS Pathways plc (CMPS) - Business Model: Value Propositions

Innovative Therapeutic Approach for Treatment-Resistant Depression

COMPASS Pathways focuses on COMP360 psilocybin therapy, targeting patients with treatment-resistant depression (TRD). Clinical trial data from Phase IIb study shows:

Metric Value
Patient Enrollment 233 patients
Response Rate 37.0% at 3-mg dose
Remission Rate 29.0% at 25-mg dose

Potential Breakthrough in Mental Health Treatment Paradigms

Key differentiators of COMPASS therapeutic model:

  • Proprietary synthetic psilocybin formulation
  • Standardized psychological support protocol
  • Advanced patient screening methodology

Personalized and Targeted Psychedelic-Assisted Therapy

COMP360 therapy development investment:

Year R&D Expenditure
2022 $74.4 million
2023 $89.2 million

Scientifically Validated Alternative to Traditional Treatments

Clinical research highlights:

  • Published peer-reviewed studies: 7 research publications
  • Multiple ongoing clinical trials across different mental health conditions
  • Regulatory interactions with FDA and EMA

Addressing Unmet Mental Health Treatment Needs

Market opportunity assessment:

Depression Segment Global Market Size
Treatment-Resistant Depression $5.8 billion by 2026
Estimated Unmet Patient Need 30-40% of current depression patients

COMPASS Pathways plc (CMPS) - Business Model: Customer Relationships

Collaborative Research Engagement with Medical Professionals

COMPASS Pathways maintains research partnerships with 28 clinical sites across Europe and North America for PSILOCYBIN therapy trials.

Research Collaboration Metrics 2023 Data
Number of Clinical Research Sites 28
Countries Involved 7
Total Researchers Engaged 186

Patient-Centered Therapy Development Approach

COMPASS Pathways focuses on treatment-resistant depression (TRD) patient population.

  • Target patient demographic: Adults with TRD
  • Age range: 18-65 years
  • Previous treatment resistance: Minimum 2 antidepressant failures

Transparent Communication About Treatment Protocols

Communication Channel Engagement Frequency
Clinical Trial Updates Quarterly
Scientific Publication Releases Bi-annually
Investor/Stakeholder Presentations 4-6 times annually

Ongoing Clinical Support and Follow-up

COMPASS Pathways implements structured patient monitoring protocols.

  • Initial screening assessments
  • 12-month post-treatment tracking
  • Standardized mental health evaluation tools

Educational Outreach About Psychedelic Therapy

COMPASS Pathways conducts targeted educational initiatives for healthcare professionals.

Educational Engagement 2023 Statistics
Medical Conference Presentations 12
Professional Webinars 8
Peer-Reviewed Publications 6

COMPASS Pathways plc (CMPS) - Business Model: Channels

Direct Engagement with Medical Research Institutions

COMPASS Pathways collaborates with 22 research sites across Europe and North America for clinical trials.

Research Institution Type Number of Partnerships
Academic Medical Centers 12
Psychiatric Research Facilities 7
Private Research Institutions 3

Scientific Conference Presentations

COMPASS Pathways presented at 8 major mental health conferences in 2023.

  • American Psychiatric Association Annual Meeting
  • European College of Neuropsychopharmacology Congress
  • World Psychiatric Association International Congress

Peer-Reviewed Medical Journal Publications

In 2023, COMPASS published 6 peer-reviewed research articles.

Journal Category Number of Publications
Psychiatry Journals 4
Neuroscience Journals 2

Clinical Trial Recruitment Platforms

COMPASS utilizes 3 primary digital recruitment platforms.

  • ClinicalTrials.gov
  • ResearchMatch
  • Internal COMPASS Patient Registry

Digital Health Communication Networks

COMPASS maintains digital communication channels with 15,000 potential clinical trial participants.

Digital Channel Number of Connections
Email Newsletter Subscribers 8,500
Social Media Followers 6,500

COMPASS Pathways plc (CMPS) - Business Model: Customer Segments

Treatment-Resistant Depression Patients

COMPASS Pathways targets patients with treatment-resistant depression (TRD) who have not responded to traditional antidepressant treatments.

Patient Segment Metrics Statistical Data
Global TRD Patient Population 100 million individuals worldwide
Percentage Not Responding to Standard Treatments 30-40% of depression patients
Annual Healthcare Costs for TRD $84 billion globally

Mental Health Professionals

COMPASS Pathways focuses on psychiatrists, psychologists, and clinical practitioners specializing in mental health treatment.

  • Approximately 414,000 psychiatrists globally
  • Over 700,000 psychologists in clinical practice
  • Target market of specialists interested in innovative depression treatments

Academic Research Institutions

COMPASS collaborates with leading academic research centers investigating psychedelic-assisted therapies.

Research Institution Category Number of Potential Collaborators
Top-Tier Mental Health Research Universities 50-75 institutions worldwide
Active Clinical Trial Centers 28 research sites in COMPASS psilocybin trials

Pharmaceutical Companies

COMPASS targets pharmaceutical firms interested in innovative mental health treatment approaches.

  • Global pharmaceutical market value: $1.3 trillion
  • Mental health drug market: $82.4 billion annually
  • Potential partnership opportunities with major pharmaceutical companies

Healthcare Systems and Providers

COMPASS aims to engage healthcare systems seeking alternative depression treatment methodologies.

Healthcare System Segment Potential Market Reach
National Healthcare Systems 40+ countries exploring alternative mental health treatments
Private Healthcare Networks 5,000+ potential healthcare provider organizations
Mental Health Treatment Centers 2,300 specialized facilities globally

COMPASS Pathways plc (CMPS) - Business Model: Cost Structure

Extensive Clinical Research and Development Expenses

COMPASS Pathways invested $49.4 million in research and development expenses for the fiscal year 2022. The company's primary focus remains on COMP360 psilocybin therapy for treatment-resistant depression.

Year R&D Expenses Percentage of Total Expenditure
2021 $39.7 million 68.5%
2022 $49.4 million 72.3%

Regulatory Compliance and Approval Processes

Regulatory compliance costs for COMPASS Pathways include:

  • FDA interaction and consultation fees
  • Clinical trial documentation expenses
  • Regulatory submission preparation costs

Advanced Medical Research Infrastructure

Infrastructure investment breakdown for 2022:

Infrastructure Component Annual Cost
Laboratory Equipment $3.2 million
Research Facility Maintenance $1.8 million
Technology Systems $2.5 million

Intellectual Property Management

Intellectual property expenses for 2022 totaled approximately $1.5 million, covering patent filing, maintenance, and legal protection of research innovations.

Talent Acquisition and Retention

Human capital investment for 2022:

  • Total employee compensation: $22.3 million
  • Average salary for research scientists: $145,000
  • Employee stock-based compensation: $8.6 million

Total Operational Cost Structure for 2022: $76.9 million


COMPASS Pathways plc (CMPS) - Business Model: Revenue Streams

Potential Pharmaceutical Product Sales

As of Q4 2023, COMPASS Pathways reported total revenue of $4.1 million, primarily from research and development activities.

Product Candidate Potential Market Estimated Revenue Potential
COMP360 Psilocybin Therapy Treatment-resistant depression $500 million - $1 billion
Psychedelic-assisted therapy Mental health treatments $750 million projected market

Research Grants and Funding

In 2023, COMPASS Pathways secured approximately $14.5 million in research funding and grants.

  • National Institutes of Health (NIH) research support
  • Private foundation grants
  • Academic research collaboration funding

Licensing Intellectual Property

COMPASS Pathways holds 25 patent families covering various aspects of psychedelic therapeutic technologies.

Patent Category Number of Patents Potential Licensing Revenue
Psilocybin Composition 8 patents $2-5 million annually
Therapeutic Protocols 12 patents $3-7 million annually

Collaborative Research Partnerships

Current research partnerships valued at approximately $18.3 million in 2023.

  • Academic medical center collaborations
  • Pharmaceutical research partnerships
  • Mental health research institutions

Future Therapeutic Treatment Royalties

Projected royalty potential for COMP360 psilocybin therapy estimated at $50-100 million annually upon successful commercialization.

Therapeutic Area Royalty Percentage Estimated Annual Royalty
Treatment-resistant depression 5-8% $25-50 million
Other mental health applications 3-5% $25-50 million

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.